Aldy Aldy

Aldy is a clinical-stage biotechnology company dedicated to developing therapies that enhance metabolic health by targeting the enzyme aldehyde dehydrogenase 2 (ALDH2). The company's lead candidate, also named Aldy, is a small molecule activator of ALDH2 designed to accelerate the detoxification of acetaldehyde, a toxic byproduct of alcohol metabolism. This approach primarily targets Alcohol Flush Syndrome, a genetic condition affecting millions, particularly in East Asian populations, which increases the risk of esophageal cancer and other metabolic issues. Beyond alcohol metabolism, Aldy is exploring the broader potential of ALDH2 activation to mitigate oxidative stress and cellular damage in various metabolic and cardiovascular diseases. The company was founded based on pioneering research from Stanford University and is backed by prominent venture capital firms.